ArticleJournal of hepatocellular carcinoma2025
AI-Based Quantification of Enhancing Tumor Volume on Contrast-Enhanced MRI to Predict Pathologic Response and Prognosis in HCC After HAIC Plus Targeted Therapy and Immunotherapy.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Opportunistic Promptable Segmentation: Leveraging Routine Radiological Annotations to Guide 3D CT Lesion Segmentation.Journal of imaging informatics in medicine · 2026Article
- Artificial Intelligence in the Diagnosis and Prognostic Stratification of Hepatocellular Carcinoma: Current Evidence, Clinical Applications, and Future Perspectives.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To explore the diagnostic and prognostic value of AI-quantified MRI tumor volume for assessing pathologic response in unresectable hepatocellular carcinoma (uHCC) after hepatic arterial infusion chemotherapy plus targeted therapy and immunotherapy (HAIC-TI). Materials and Methods: This retrospective study included 35 patients (46 lesions) who underwent HAIC-TI followed by hepatectomy. AI was used to calculate the tumor enhancement volume ratio (TEVR) from MRI. Correlation analysis was conducted to evaluate the relationship between TEVR and pathological tissue proportions. Receiver operating characteristic (ROC) curve determined the optimal cutoff for the ratio of viable tumor cells (RVTCs) to define major pathological response (MPR). The diagnostic performance of AI for MPR and its prognostic significance in recurrence-free survival (RFS) were assessed. Results: TEVR in portal venous phase is strongly correlated with non-necrotic tissue ratio (r = 0.89, Conclusion: AI-based MRI quantification of TEVR effectively reflected pathologic response and served as a non-invasive prognostic marker for postoperative recurrence in uHCC patients after HAIC-TI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.